Tandem Diabetes Care (TNDM) Enterprise Value Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Tandem Diabetes Care | 1.31 Bn | 739.55 Mn | 136.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.15% |
| Dec 31, 2025 | 22.01% |
| Sep 30, 2025 | 19.37% |
| Jun 30, 2025 | 20.82% |
| Mar 31, 2025 | 16.60% |
| Dec 31, 2024 | 11.10% |
| Sep 30, 2024 | 7.34% |
| Jun 30, 2024 | 6.03% |
| Mar 31, 2024 | 3.05% |
| Dec 31, 2023 | 1.18% |
| Sep 30, 2023 | -2.36% |
| Jun 30, 2023 | -5.97% |
| Mar 31, 2023 | -48.02% |
| Dec 31, 2022 | -51.77% |
| Sep 30, 2022 | -57.12% |
| Jun 30, 2022 | -69.10% |
| Mar 31, 2022 | -71.66% |
| Dec 31, 2021 | -69.09% |
| Sep 30, 2021 | -45.08% |
| Jun 30, 2021 | -84.73% |
| Mar 31, 2021 | -92.59% |
| Dec 31, 2020 | -224.60% |
| Sep 30, 2020 | -198.62% |
| Jun 30, 2020 | -148.46% |
| Mar 31, 2020 | -66.74% |
| Dec 31, 2019 | -153.28% |
| Sep 30, 2019 | -66.38% |
| Jun 30, 2019 | -34.24% |
| Mar 31, 2019 | -22.44% |
| Dec 31, 2018 | -21.97% |
| Sep 30, 2018 | -33.58% |
| Jun 30, 2018 | 3.99% |
| Mar 31, 2018 | 14.84% |
| Dec 31, 2017 | 40.49% |
| Sep 30, 2017 | 39.78% |
| Jun 30, 2017 | 33.45% |
| Mar 31, 2017 | 32.18% |
| Dec 31, 2016 | 56.23% |
| Sep 30, 2016 | -29.89% |
| Jun 30, 2016 | -21.70% |
| Mar 31, 2016 | -32.47% |